Scinai Immunotherapeutics Prepares for BIO-Europe Spring 2026 to Enhance Global Biopharma Presence
- Scinai Immunotherapeutics will debut at BIO-Europe Spring® 2026 to highlight its CDMO services and innovative therapeutics.
- The company aims to showcase its antibody-based immunotherapies targeting autoimmune diseases, licensed from renowned institutions.
- Scinai's acquisition of Recipharm Israel strengthens its manufacturing capabilities, fostering partnerships in the pharmaceutical industry.
Scinai Immunotherapeutics: Strengthening Presence in Global Biopharmaceutical Landscape
Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on innovative inflammation and immunology therapeutics, gears up for its important debut at the BIO-Europe Spring® 2026 conference in Lisbon, Portugal, from March 23 to 25. This noteworthy participation follows Scinai's recent acquisition of Recipharm Israel, which significantly enhances its development and manufacturing capabilities. With a delegation led by CEO Amir Reichman, accompanied by other key executives including Solomon Gahtan and Dr. Helen Domeshek, Scinai aims to connect with pharmaceutical and biotechnology firms, investors, and potential clients to highlight its advanced research and integrated contract development and manufacturing organization (CDMO) services.
At the conference, Scinai seeks to establish itself as a key player in the biopharmaceutical industry by showcasing its comprehensive CDMO platform. This platform is structured around three strategic pillars: a current Good Manufacturing Practice (cGMP) biologics site located in Jerusalem, a recently acquired cGMP small-molecule active pharmaceutical ingredient (API) facility in Yavne from Recipharm, and a collaborative partnership with Recipharm itself. This collaboration enables Scinai to access cutting-edge subcontracting technologies and offers clients a seamless transition from the preclinical phases of development to commercial production. By minimizing risks and expediting timelines, Scinai positions itself as a reliable partner for biopharmaceutical companies aiming to bring innovative therapies to market.
In addition to its CDMO capabilities, Scinai also intends to leverage the conference as a platform to present its extensive pipeline of antibody-based immunotherapies targeting autoimmune and inflammatory diseases, with a particular focus on dermatology. The assets that underpin this pipeline are licensed from prestigious institutions such as the Max Planck Society and the University Medical Center Göttingen. Scinai’s participation in BIO-Europe Spring underscores its commitment to advancing therapeutic offerings, bolstering its reputation as a significant player in the CDMO landscape, and illustrating the company's vision of leveraging innovation to improve patient outcomes globally.
In related developments, Scinai's enhanced capacity from the acquisition of Recipharm Israel is expected to attract new partnerships and collaborations within the pharmaceutical industry. By reinforcing its manufacturing and development infrastructure, Scinai opens new avenues for working with both established and emerging players in the sector. This strategic positioning aims to create an ecosystem for efficient and effective therapeutic solutions that cater to the growing demand for immunomodulatory treatments.
As these developments unfold, Scinai Immunotherapeutics remains committed to driving its research efforts forward while actively engaging in the vibrant international biopharmaceutical community. The upcoming conference is poised to be a landmark opportunity for Scinai to solidify its presence in the industry and to promote its vision for the future of immunotherapy.